Bio-Techne Overview

  • Year Founded
  • 1976

Year Founded

  • Status
  • Public

  • Employees
  • 3,000

Employees

  • Stock Symbol
  • TECH

Stock Symbol

  • Investments
  • 34

  • Share Price
  • $72.71
  • (As of Thursday Closing)

Bio-Techne General Information

Description

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Contact Information

Formerly Known As
Techne
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 614 McKinley Place North East
  • Minneapolis, MN 55413
  • United States
+1 (612)
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Diagnostic Equipment
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 614 McKinley Place North East
  • Minneapolis, MN 55413
  • United States
+1 (612)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bio-Techne Stock Performance

As of 19-Nov-2026, Bio-Techne’s stock price is $72.71. Its current market cap is $11.4B with 157M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$72.71 $72.75 $43.20 - $72.88 $11.4B 157M 2.91M $1.10

Bio-Techne Financials Summary

As of 30-Sep-2026, Bio-Techne has a trailing 12-month revenue of $1.23B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 30-Jun-2026 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024
EV 11,388,993 11,088,526 8,348,506 11,640,357
Revenue 1,228,196 1,215,039 1,219,635 1,159,060
EBITDA 327,786 343,446 212,989 309,813
Net Income 171,970 181,862 73,400 168,105
Total Assets 2,636,820 2,586,726 2,557,868 2,703,867
Total Debt 285,555 289,087 444,058 419,538
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bio-Techne Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bio-Techne‘s full profile, request access.

Request a free trial

Bio-Techne Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, bio
Discovery Tools (Healthcare)
Minneapolis, MN
3,000 As of 2026

Hercules, CA
 

Cincinnati, OH
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bio-Techne Competitors (19)

One of Bio-Techne’s 19 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bio-Rad Laboratories Corporation Hercules, CA
Meridian Bioscience Private Equity-Backed Cincinnati, OH
Thermo Fisher Scientific Formerly PE-Backed Waltham, MA
Revvity Corporation Waltham, MA
BioMérieux Formerly PE-Backed Marcy-l'Etoile, France
You’re viewing 5 of 19 competitors. Get the full list »

Bio-Techne Patents

Bio-Techne Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026231614-A1 Engineered fgf4 polypeptides, compositions, and uses thereof Pending 28-Apr-2025
WO-2026178548-A1 Engineered fgf10 polypeptides, compositions, and uses thereof Pending 24-Feb-2025
WO-2026151761-A1 Engineered il-15 polypeptides, compositions, and uses thereof Pending 07-Jan-2025
WO-2026076112-A1 Variants of activin a Pending 01-Oct-2024
WO-2026029980-A1 True spectral flow cytometers Pending 15-Jul-2024 G01N15/1434
To view Bio-Techne’s complete patent history, request access »

Bio-Techne Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bio-Techne Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bio-Techne‘s full profile, request access.

Request a free trial

Bio-Techne Investments & Acquisitions (34)

Bio-Techne’s most recent deal was a Early Stage VC with Spear Bio for . The deal was made on 23-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Spear Bio 23-Jul-2024 Early Stage VC Other Healthcare Technology Systems
Lunaphore 07-Jul-2023 Merger/Acquisition Diagnostic Equipment
Wilson Wolf Manufacturing 31-Mar-2023 Corporate Diagnostic Equipment
Namocell 30-Jun-2022 Merger/Acquisition Biotechnology
Asuragen 06-Apr-2021 Merger/Acquisition Diagnostic Equipment
You’re viewing 5 of 34 investments and acquisitions. Get the full list »

Bio-Techne ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

26.49 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Bio-Techne’s complete esg history, request access »

Bio-Techne Exits (7)

Bio-Techne’s most recent exit was on 01-Aug-2018 from Exosome Diagnostics. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Exosome Diagnostics 01-Aug-2018 Completed
Astute Medical 14-Dec-2016 Completed
  • 2 buyers
Chemocentryx 08-Feb-2012 Completed
  • 2 buyers
Chemocentryx 08-Mar-2007 Completed
  • 6 buyers
Chemocentryx 18-Jun-2004 Later Stage VC Completed
  • 8 buyers
You’re viewing 5 of 7 exits. Get the full list »

Bio-Techne Affiliates

Subsidiaries (9)

Name Industry Location Year Founded
Lunaphore Tolochenaz, Switzerland 2014
Advanced Cell Diagnostics Minneapolis, MN 2006
Shanghai PrimeGene Bio-Tech Company Shanghai, China 2006
Asuragen Austin, TX 2005
Eurocell Diagnostics Rennes, France 2003
You’re viewing 5 of 9 affiliates. Get the full list.  »

Bio-Techne FAQs

  • When was Bio-Techne founded?

    Bio-Techne was founded in 1976.

  • Where is Bio-Techne headquartered?

    Bio-Techne is headquartered in Minneapolis, MN.

  • What is the size of Bio-Techne?

    Bio-Techne has 3,000 total employees.

  • What industry is Bio-Techne in?

    Bio-Techne’s primary industry is Discovery Tools (Healthcare).

  • Is Bio-Techne a private or public company?

    Bio-Techne is a Public company.

  • What is Bio-Techne’s stock symbol?

    The ticker symbol for Bio-Techne is TECH.

  • What is the current stock price of Bio-Techne?

    As of 19-Nov-2026 the stock price of Bio-Techne is $72.71.

  • What is the current market cap of Bio-Techne?

    The current market capitalization of Bio-Techne is $11.4B.

  • What is Bio-Techne’s current revenue?

    The trailing twelve month revenue for Bio-Techne is $1.23B.

  • Who are Bio-Techne’s competitors?

    Bio-Rad Laboratories, Meridian Bioscience, Thermo Fisher Scientific, Revvity, and BioMérieux are some of the 19 competitors of Bio-Techne.

  • What is Bio-Techne’s annual earnings per share (EPS)?

    Bio-Techne’s EPS for 12 months was $1.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process